Owkin, an AI-Biotech Unicorn, Brings Its Cutting-Edge AI to Germany, Austria and Switzerland to Accelerate Research
03 July 2024 - 8:00AM
Business Wire
- Partnering with nine hospitals in Germany, Austria and
Switzerland, Owkin will accelerate research across numerous
therapeutic areas to understand unique patient biology better
- Owkin will bring its world-class data access and AI to the
forefront of drug discovery and development, analysing multimodal
patient data in a privacy-enhanced way
Owkin, the first end-to-end AI-biotech unicorn that provides
best-in-class AI-driven precision drug discovery, development and
diagnostics, has announced its expansion into the DACH region
(Germany, Austria and Switzerland) following partnerships with nine
of the top centers in the region, including Charité –
Universitätsmedizin Berlin, Centre Hospitalier Universitaire
Vaudois (CHUV), Universitätsspital Basel, Technische Universität
München (TUM), Uniklinikum Erlangen, Universitätsklinikum Leipzig,
Inselspital Bern, Universitätsklinik Mannheim-Heidelberg and
Medizinische Universität Wien. These collaborations signify
unparalleled representation of patient populations, representing
24% of all outpatient cases and 15% of the total patients in the
DACH region.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240703400559/en/
Guillaume Bézie, Director of Partnerships Western Europe:
“The Western Europe network covering France, Benelux and DACH
represents the largest pool of centres for Owkin. Partnering with
top academic institutions is an inevitable asset for our expansion
strategy, and we are delighted to showcase the ability to
significantly increase our footprint in the DACH region. By
capturing the diverse landscape of human health, we empower our AI
to better address the unique needs of all individuals. With our
partners, we are fully committed to accelerate the secondary use of
multimodal patient data for the purpose of giving the right
treatment for each patient.”
By analyzing vast datasets and identifying complex patterns
across the nine hospitals, Owkin will use its AI engines and
diagnostic tools to improve patient outcomes in Prostate Cancer,
Muscle Invasive Bladder Cancer (MIBC), and Cardiovascular Disease
(CVD). This will enable researchers to discover novel biomarkers,
predict treatment responses, and develop more effective therapies
tailored to individual patients.
- BiomarkerPlus (Outcome prediction): Owkin will work with
Inselspital Bern, Technische Universität München (TUM) and
Universitätsspital Basel to analyze multimodal patient data to
identify which early-stage prostate cancer patients are most likely
to fail primary curative treatment and ultimately progress to more
severe disease and anticipate if they may benefit from a different
management strategy. Owkin is also partnering with Uniklinikum
Erlangen (UKER) on MIBC to analyze H&E slides to detect FGFR3
mutations.
- TargetMatch (Target discovery): In partnership with
Medizinische Fakultät Mannheim der Ruprecht-Karls-Universität and
Medizinische Universität Wien, Owkin will access a high-quality
multimodal dataset, including digitized histology and RNA-seq, to
better understand the response to treatment for neoadjuvant
chemotherapy and to identify new targets and treatment strategies
in MIBC.
- TrialPlus (Clinical trial optimization): Owkin’s
partnership with Universitätsklinikum Leipzig aims to use machine
learning techniques to enhance clinical trial design for CVD.
- AI Diagnostics (MSIntuit® CRC): To further improve
Owkin’s first CE-IVD-approved MSI pre-screening tool MSIntuit® CRC,
Owkin will work in close collaboration with Uniklinikum Erlangen
(UKER) to validate our upgraded MSIntuit CRC V2 on more diverse
cohorts.
In addition to advancing research towards more personalized
treatment strategies for patients with prostate cancer, MIBC and
CVD, Owkin has also expanded its MOSAIC network, a global
initiative to build the world’s largest spatial omics dataset in
oncology with 7,000 patient samples across 7 cancer indications,
bringing on Uniklinikum Erlangen, Charité – Universitätsmedizin
Berlin and Centre Hospitalier Universitaire Vaudois (CHUV) to
accelerate research across numerous therapeutic areas.
Dr. Philipp Mann, Principal Partnerships Manager Switzerland,
Germany and Austria (DACH) said: “The healthcare system across
the DACH region is an invaluable asset because it offers an
extensive repository of reliable, comprehensive health data that
can guide drug discovery and development strategies. The
collaboration between Owkin and these institutions enhances the use
of this data, driving innovation and fast-tracking medical
advancements. With the combined expertise of these partners, the
data can be transformed into actionable insights used to
revolutionize patient care and improve health outcomes.”
About Owkin
Owkin is the first end-to-end AI-biotech unicorn on a mission to
understand complex biology and derive new multimodal biomarkers
through AI. We identify precision therapeutics, de-risk and
accelerate clinical trials and develop diagnostics using AI trained
on world-class patient data through privacy-enhancing federated
technologies. We merge wet lab experiments with advanced AI
techniques to create a powerful feedback loop for accelerated
discovery and innovation in oncology, cardiovascular, immunity and
inflammation. Owkin also founded MOSAIC, the world’s largest
spatial multi-omics atlas for cancer research. Owkin has raised
over $300 million through investments from leading biopharma
companies, including Sanofi and BMS, and venture funds like
Fidelity, GV and Bpifrance, among others.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240703400559/en/
stephanie.libous@owkin.com